KPV Australia

KPV Australia. KPV (Lysine-Proline-Valine) is a synthetic tripeptide studied in laboratory research — the C-terminal fragment of α-melanocyte-stimulating hormone (α-MSH) — referenced across the gastrointestinal, immune and anti-inflammatory pathway literature. The Elite AU Peptides KPV is independently HPLC-tested by Janoshik; the certificate of analysis is published on this page and in the lab-reports library, with the measured number and an independently verifiable Janoshik key.

Supplied in 10 mg lyophilised vials, AU-domestic, AUD pricing. Every batch is held until the independent HPLC report comes back within our acceptance threshold; nothing is listed without a certificate on file. Supplied strictly for in-vitro and laboratory research use only — not for human or animal consumption, not a therapeutic good, not TGA-approved.

KPV (CAS 67727-97-3; molecular formula C16H30N4O4, average molecular weight ≈ 342 g/mol; sequence Lys-Pro-Val) is a synthetic tripeptide composed of the three C-terminal residues of α-MSH. It is referenced across the inflammation-modulation, gastrointestinal-research and immune-research literature — most frequently cited in the inflammatory-bowel and mucosal-research strands.

Its anti-inflammatory activity in murine inflammatory-bowel-disease models was reported by Kannengiesser and colleagues (Inflammatory Bowel Diseases, 2008), who noted the effect can be independent of the classical melanocortin-receptor pharmacophore. Dalmasso and colleagues (Gastroenterology, 2008) established that KPV enters intestinal epithelial and immune cells via the PepT1 di/tripeptide transporter, where it suppresses NF-κB and pro-inflammatory-cytokine signalling.

The wider biochemistry of α-MSH and its C-terminal tripeptide is surveyed in the review by Brzoska and colleagues (Endocrine Reviews, 2008). These give KPV a well-described identity as a small, transporter-accessible anti-inflammatory research tripeptide.

KPV is referenced as one of the better-characterised tripeptide research compounds in the catalogue; researchers often pair it with healing-class compounds such as BPC-157 and TB-500 in multi-compound research protocols, and it is the fourth component of the KLOW80 research blend.

The information provided here is a research-reference summary only. Elite AU Peptides makes no medical, therapeutic, anti-inflammatory, or human-use claim about this product. KPV is not TGA-approved, is not a therapeutic good, and is supplied strictly for in-vitro and laboratory research use only. Researchers should consult the primary peer-reviewed literature for pathway data and protocol-specific reference values.

Reconstitute the lyophilised KPV vial with bacteriostatic water for laboratory handling. Add the diluent slowly down the vial wall and swirl gently rather than shaking. The required volume depends on the protocol’s downstream assay requirements — a 10 mg vial reconstituted in 5 mL of bacteriostatic water yields a 2 mg/mL working stock. Adjust per protocol.

Store the lyophilised powder at −20°C, desiccated and protected from light; once reconstituted, store refrigerated at 2–8°C and use within the documented research window, or aliquot and freeze to avoid repeated freeze-thaw cycles. Tamper-evident packaging; the batch label is the canonical reference for the certificate of analysis published in the lab-reports library.

Shop bacteriostatic water

Australia only. Free shipping over $100. Orders placed before 12pm AEST are dispatched the same business day from Australia.

30-day returns on unused product in original packaging, with prior approval.